Brimonidine for Intraoperative Hemostasis

Status Recruiting

Clinical Trial Summary

The purpose of this study is to observe and report the effects of topical ophthalmic brimonidine in oculofacial plastic surgery.

Clinical Trial Description

Brimonidine ophthalmic solution (Alphagan) is mainstay in glaucoma therapy to reduce intraocular pressure. The medication is an alpha2 adrenergic agonist, which increases uveoscleral outflow of aqueous humor. Alpha2 agonists also have vasoconstrictive properties, which has been utilized in over-the-counter medications like Lumify for redness relief. An unexploited utility of its vasoconstrictive property is reduction in intraoperative bleeding during ophthalmic surgery. The purpose of this study is to observe and report the effects of brimonidine in oculofacial plastic surgery. There are reports in ophthalmic literature that observe the hemostatic effect of topical brimonidine across different subspecialties. It has been shown to reduce intraoperative bleeding and post-operative subconjunctival hemorrhages in pterygium removal, strabismus surgery, LASIK, and cataract surgery. One study claimed that it had a comparable hemostatic effect to phenylephrine. Many of the procedures in oculoplastic surgery involve manipulation and incision of eyelid skin and conjunctival tissue. Some examples include blepharoplasty, ptosis repair, medial spindles, lateral tarsal strips, canthotomy and cantholysis with subsequent repair, retraction repair, and orbital fracture repair. Rapid and adequate control of intraoperative bleeding is crucial to the success of oculoplastic surgery. Although surgeons take proper precautions to prevent inadequate hemostasis (discontinuing blood thinners, use of electrocautery, and administration of intradermal epinephrine), excessive bleeding can still occur. This can impair surgeon performance by obscuring visualization, and negatively affect the patient due to prolonged operative times, and delayed healing due to hematoma formation. The most feared complication of oculoplastic surgery is intraorbital hemorrhage, which can cause orbital compartment syndrome causing vision loss. Therefore, any intervention to minimize bleeding is very advantageous to the patient. Use of Brimonidine drops intraoperatively will improve hemostasis, resulting in improved visualization, reduced operative time under anesthesia, and reduced risk of significant intraorbital hemorrhage. Due to both brimonidine's vasoconstrictive properties and relatively favorable safety profile, it raises the question: can brimonidine be used to achieve better hemostasis in oculoplastic procedures? ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05480098
Study type	Interventional
Source	University of Louisville
Contact	Christopher Compton, MD
Phone	5025880550
Email	christopher.compton@louisville.edu
Status	Recruiting
Phase	Phase 4
Start date	May 26, 2022
Completion date	December 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04585217` - A Comparison of the Effect of Suture Material on Blepharoplasty Incision	N/A
Recruiting	`NCT05890027` - Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation	Phase 4
Completed	`NCT06047418` - Blepharoptosis in Indonesia: A 5-Year Multicenter Study on Characteristics and Surgical Evaluation
Completed	`NCT04831047` - The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance	Phase 4
Active, not recruiting	`NCT04678115` - Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis	N/A
Not yet recruiting	`NCT04235803` - Telemedicine Follow-up for Routine, Low-Risk Oculoplastic Surgery	N/A
Completed	`NCT05770973` - Effect of Eyelid Patching After Ptosis Surgery	N/A
Completed	`NCT00753831` - Efficacy of Aurosling in Frontalis Sling Suspension Surgery	Phase 4
Completed	`NCT04291625` - Evaluation of Intraoperative Lagophthalmos Formula	N/A
Enrolling by invitation	`NCT03916107` - Comparison of Different Surgical Treatments for Severe Ptosis Correction	N/A
Completed	`NCT03818204` - Clinical Trial to Improve the Magnetic Levator Prosthesis	N/A
Recruiting	`NCT05750251` - Effect of Upper Eyelid Surgeries on Corneal Characteristics
Not yet recruiting	`NCT03392272` - Modified Müller's Muscle-conjunctival Resection Internal Ptosis Repair Using Fibrin Glue	N/A
Recruiting	`NCT01616108` - Bupivacaine Injection of Eye Muscles to Treat Strabismus	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.